Joseph Catanzaro
Stock Analyst at Mizuho
(3.89)
# 813
Out of 5,182 analysts
110
Total ratings
48.91%
Success rate
10.94%
Average return
Main Sectors:
Stocks Rated by Joseph Catanzaro
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CLYM Climb Bio | Initiates: Outperform | $18 | $8.82 | +104.08% | 1 | Apr 15, 2026 | |
| APGE Apogee Therapeutics | Maintains: Outperform | $105 → $110 | $93.77 | +17.31% | 2 | Mar 30, 2026 | |
| CTMX CytomX Therapeutics | Maintains: Overweight | $10 → $12 | $4.95 | +142.42% | 7 | Mar 23, 2026 | |
| ERAS Erasca | Maintains: Outperform | $16 → $19 | $19.22 | -1.14% | 1 | Mar 13, 2026 | |
| TNGX Tango Therapeutics | Maintains: Outperform | $19 → $20 | $25.13 | -20.41% | 3 | Mar 11, 2026 | |
| EIKN Eikon Therapeutics | Initiates: Outperform | $26 | $11.86 | +119.22% | 1 | Mar 2, 2026 | |
| NRIX Nurix Therapeutics | Maintains: Overweight | $32 → $35 | $17.12 | +104.44% | 5 | Jan 29, 2026 | |
| IBRX ImmunityBio | Maintains: Overweight | $5 → $7 | $7.63 | -8.20% | 6 | Jan 20, 2026 | |
| RVMD Revolution Medicines | Maintains: Outperform | $90 → $143 | $147.05 | -2.75% | 4 | Jan 13, 2026 | |
| AVTX Avalo Therapeutics | Initiates: Outperform | $39 | $14.90 | +161.74% | 1 | Dec 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $51 | $10.45 | +388.27% | 1 | Dec 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $18 | $24.03 | -25.09% | 1 | Dec 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $53 | $72.87 | -27.27% | 1 | Dec 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $81 → $120 | $87.75 | +36.75% | 2 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $48 | $34.53 | +39.01% | 1 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $7.5 → $6 | $3.88 | +54.64% | 10 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $50 → $45 | $12.12 | +271.29% | 3 | Feb 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $105 → $110 | $137.80 | -20.17% | 5 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $37 → $38 | $45.15 | -15.84% | 4 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 → $15 | $11.84 | +26.69% | 3 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $52 → $53 | $68.47 | -22.59% | 9 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $7 → $10 | $1.79 | +458.66% | 4 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $19 | $1.96 | +869.39% | 5 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $19 | $11.02 | +72.41% | 1 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $12 → $15 | $3.07 | +389.40% | 3 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $36 | $9.94 | +262.17% | 2 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $40 | $21.46 | +86.39% | 5 | Jul 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $15 | $9.19 | +63.22% | 4 | Jun 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $4.5 | $2.35 | +91.49% | 1 | May 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $26 → $30 | $1.75 | +1,614.29% | 2 | Apr 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $20 | $1.65 | +1,112.64% | 1 | Apr 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $15 → $1.75 | $2.25 | -22.22% | 2 | May 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $18 → $20 | $26.03 | -23.17% | 1 | Dec 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $25 → $1.5 | $2.98 | -49.66% | 1 | May 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $240 → $200 | $29.97 | +567.33% | 2 | Mar 10, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $16.22 | +115.78% | 1 | Jun 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $60 | $1.66 | +3,514.46% | 1 | Mar 25, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $18 | $2.45 | +634.69% | 3 | Apr 7, 2020 |
Climb Bio
Apr 15, 2026
Initiates: Outperform
Price Target: $18
Current: $8.82
Upside: +104.08%
Apogee Therapeutics
Mar 30, 2026
Maintains: Outperform
Price Target: $105 → $110
Current: $93.77
Upside: +17.31%
CytomX Therapeutics
Mar 23, 2026
Maintains: Overweight
Price Target: $10 → $12
Current: $4.95
Upside: +142.42%
Erasca
Mar 13, 2026
Maintains: Outperform
Price Target: $16 → $19
Current: $19.22
Upside: -1.14%
Tango Therapeutics
Mar 11, 2026
Maintains: Outperform
Price Target: $19 → $20
Current: $25.13
Upside: -20.41%
Eikon Therapeutics
Mar 2, 2026
Initiates: Outperform
Price Target: $26
Current: $11.86
Upside: +119.22%
Nurix Therapeutics
Jan 29, 2026
Maintains: Overweight
Price Target: $32 → $35
Current: $17.12
Upside: +104.44%
ImmunityBio
Jan 20, 2026
Maintains: Overweight
Price Target: $5 → $7
Current: $7.63
Upside: -8.20%
Revolution Medicines
Jan 13, 2026
Maintains: Outperform
Price Target: $90 → $143
Current: $147.05
Upside: -2.75%
Avalo Therapeutics
Dec 18, 2025
Initiates: Outperform
Price Target: $39
Current: $14.90
Upside: +161.74%
Dec 18, 2025
Initiates: Outperform
Price Target: $51
Current: $10.45
Upside: +388.27%
Dec 18, 2025
Initiates: Neutral
Price Target: $18
Current: $24.03
Upside: -25.09%
Dec 18, 2025
Initiates: Outperform
Price Target: $53
Current: $72.87
Upside: -27.27%
Dec 11, 2025
Maintains: Outperform
Price Target: $81 → $120
Current: $87.75
Upside: +36.75%
Oct 21, 2025
Initiates: Outperform
Price Target: $48
Current: $34.53
Upside: +39.01%
Feb 28, 2025
Maintains: Neutral
Price Target: $7.5 → $6
Current: $3.88
Upside: +54.64%
Feb 27, 2025
Maintains: Overweight
Price Target: $50 → $45
Current: $12.12
Upside: +271.29%
Feb 12, 2025
Maintains: Overweight
Price Target: $105 → $110
Current: $137.80
Upside: -20.17%
Feb 12, 2025
Maintains: Overweight
Price Target: $37 → $38
Current: $45.15
Upside: -15.84%
Jan 17, 2025
Maintains: Overweight
Price Target: $40 → $15
Current: $11.84
Upside: +26.69%
Jan 10, 2025
Maintains: Neutral
Price Target: $52 → $53
Current: $68.47
Upside: -22.59%
Dec 13, 2024
Maintains: Overweight
Price Target: $7 → $10
Current: $1.79
Upside: +458.66%
Oct 31, 2024
Maintains: Overweight
Price Target: $10 → $19
Current: $1.96
Upside: +869.39%
Oct 7, 2024
Initiates: Overweight
Price Target: $19
Current: $11.02
Upside: +72.41%
Sep 23, 2024
Maintains: Overweight
Price Target: $12 → $15
Current: $3.07
Upside: +389.40%
Aug 15, 2024
Maintains: Overweight
Price Target: $36
Current: $9.94
Upside: +262.17%
Jul 8, 2024
Maintains: Overweight
Price Target: $40
Current: $21.46
Upside: +86.39%
Jun 14, 2024
Maintains: Overweight
Price Target: $15
Current: $9.19
Upside: +63.22%
May 16, 2024
Initiates: Overweight
Price Target: $4.5
Current: $2.35
Upside: +91.49%
Apr 25, 2024
Maintains: Overweight
Price Target: $26 → $30
Current: $1.75
Upside: +1,614.29%
Apr 22, 2024
Initiates: Overweight
Price Target: $20
Current: $1.65
Upside: +1,112.64%
May 23, 2023
Downgrades: Neutral
Price Target: $15 → $1.75
Current: $2.25
Upside: -22.22%
Dec 20, 2022
Maintains: Overweight
Price Target: $18 → $20
Current: $26.03
Upside: -23.17%
May 5, 2022
Downgrades: Neutral
Price Target: $25 → $1.5
Current: $2.98
Upside: -49.66%
Mar 10, 2022
Maintains: Overweight
Price Target: $240 → $200
Current: $29.97
Upside: +567.33%
Jun 21, 2021
Initiates: Overweight
Price Target: $35
Current: $16.22
Upside: +115.78%
Mar 25, 2021
Initiates: Overweight
Price Target: $60
Current: $1.66
Upside: +3,514.46%
Apr 7, 2020
Maintains: Overweight
Price Target: $28 → $18
Current: $2.45
Upside: +634.69%